摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-肼基-8-甲氧基-2-甲基喹啉 | 49612-19-3

中文名称
4-肼基-8-甲氧基-2-甲基喹啉
中文别名
——
英文名称
4-hydrazinyl-8-methoxy-2-methylquinoline
英文别名
4-hydrazino-8-methoxy-2-methylquinoline;4-hydrazino-8-methoxy-2-methyl-quinoline;(8-methoxy-2-methylquinolin-4-yl)hydrazine
4-肼基-8-甲氧基-2-甲基喹啉化学式
CAS
49612-19-3
化学式
C11H13N3O
mdl
——
分子量
203.244
InChiKey
VOLZQVKMAWUFBE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.18
  • 拓扑面积:
    60.2
  • 氢给体数:
    2
  • 氢受体数:
    4

SDS

SDS:dd1e336790761020806e9e5761682748
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    Pellerano; Savini, Farmaco, Edizione Scientifica, 1984, vol. 39, # 8, p. 681 - 685
    摘要:
    DOI:
  • 作为产物:
    描述:
    (8-甲氧基-2-甲基喹啉-4-基)肼盐酸盐 作用下, 以93%的产率得到4-肼基-8-甲氧基-2-甲基喹啉
    参考文献:
    名称:
    Synthesis and some transformations of 6(8)-substituted 4-hydrazino-2-methylquinolines
    摘要:
    6(8)-Substituted 4-hydrazino-2-methylquinolines were synthesized by reaction of the corresponding 4-chloro-2-methylquinolines with hydrazine hydrate. Reactions of the title compounds with ethyl acetoacetate and acetone gave 2,4-dimethyl-1H-pyrrolo[3,2-c]quinolines and 4-(5-ethoxy-3-methyl-1H-pyrazol-1-yl)-2-methylquinolines.
    DOI:
    10.1134/s107042801003022x
点击查看最新优质反应信息

文献信息

  • Design, Synthesis, and Structure–Activity Relationship Studies of 4-Quinolinyl- and 9-Acrydinylhydrazones as Potent Antimalarial Agents
    作者:Caterina Fattorusso、Giuseppe Campiani、Gagan Kukreja、Marco Persico、Stefania Butini、Maria Pia Romano、Maria Altarelli、Sindu Ros、Margherita Brindisi、Luisa Savini、Ettore Novellino、Vito Nacci、Ernesto Fattorusso、Silvia Parapini、Nicoletta Basilico、Donatella Taramelli、Vanessa Yardley、Simon Croft、Marianna Borriello、Sandra Gemma
    DOI:10.1021/jm7012375
    日期:2008.3.13
    synthesis, and biological investigation of novel antimalarial agents with low potential to develop resistance and structurally based on a highly conjugated scaffold. Starting from a new hit, the designed modifications were performed hypothesizing a specific interaction with free heme and generation of radical intermediates. This approach provided antimalarials with improved potency against chloroquine-resistant
    疟疾是贫困地区的主要健康问题,在这些地区,人们迫切需要以负担得起的价格购买新的抗寄生虫药。我们在此报告了新型抗疟疾药物的设计,合成和生物学研究,这些药物具有发展抗药性的低潜力,并且在结构上基于高度偶联的支架。从新的命中开始,进行设计的修饰,假设与游离血红素发生特定的相互作用并产生自由基中间体。与已知药物相比,该方法为抗疟药提供了增强的抗氯喹抗疟原虫能力。确定了许多结构-活性关系(SAR)趋势,在合成的类似物中,吡咯烷基甲基亚芳基和咪唑衍生物5r,5t,发现8b和8b是新系列中最有效的抗疟药。研究了新化合物的作用机理,并评估了它们的体内活性。
  • [EN] NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS<br/>[FR] NOUVEAUX ANTAGONISTES DU RÉCEPTEUR B2 DE LA BRADYKININE
    申请人:PHARVARIS B V
    公开号:WO2019101906A1
    公开(公告)日:2019-05-31
    The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament.
    本发明涉及一种按照通式(I)的化合物,该化合物作为一种缓激肽(BK) B2受体拮抗剂;一种含有本发明中的一种或多种化合物的药物组合物;一种含有本发明中的至少一种化合物和至少一种其他活性药物成分的联合制剂;以及所述化合物的用途,包括作为药物的用途。
  • Bradykinin B2 receptor antagonists
    申请人:Pharvaris Netherlands B.V.
    公开号:US10836748B2
    公开(公告)日:2020-11-17
    The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament.
    本发明涉及一种通式(I)化合物,它可作为缓激肽(BK)B2 受体拮抗剂;涉及一种含有一种或多种本发明化合物的药物组合物;涉及一种含有至少一种本发明化合物和至少一种其它活性药物成分的复方制剂;还涉及所述化合物的用途,包括作为药物的用途。
  • Bartolucci; Cellai; Di Filippo, Il Farmaco, 1992, vol. 47, # 11, p. 1367 - 1383
    作者:Bartolucci、Cellai、Di Filippo、Segre、Brufani、Filocamo、Bianco、Guiso、Brizzi、Benedetto、Di Caro、Elia
    DOI:——
    日期:——
  • Development of antitubercular compounds based on a 4-quinolylhydrazone scaffold. Further structure–activity relationship studies
    作者:Sandra Gemma、Luisa Savini、Maria Altarelli、Pierangela Tripaldi、Luisa Chiasserini、Salvatore Sanna Coccone、Vinod Kumar、Caterina Camodeca、Giuseppe Campiani、Ettore Novellino、Sandra Clarizio、Giovanni Delogu、Stefania Butini
    DOI:10.1016/j.bmc.2009.06.051
    日期:2009.8
    A series of 4-quinolylhydrazones was synthesized and tested in vitro against Mycobacterium tuberculosis. At a concentration of 6.25 mu g/mL, most of the newly synthesized compounds displayed 100% inhibitory activity against M. tuberculosis in cellular assays. Further screening allowed the identification of very potent antitubercular agents. Compound 4c was also tested in a time-course experiment and against mtb clinical isolates, displaying interesting results. (C) 2009 Elsevier Ltd. All rights reserved.
查看更多